New peer-reviewed research adds to substantial body of scientific evidence highlighting the safety of natural kratom leaf ...
BIRMINGHAM, AL, UNITED STATES, January 8, 2026 / EINPresswire.com / — Rampart, a Birmingham, Alabama–based medical device ...
Accepted into StartX Spring 2026, AI-Stroke advances U.S. EMS stroke research with new advisors, clinical studies, and ...
SAN DIEGO, CA / ACCESS Newswire / January 7, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or ...
LEXINGTON, Mass. and AMSTERDAM, May 29, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, ...
Phase I human study and preclinical evaluations of OcuRing™-K showed no treatment-related safety concerns, supporting ...
SEATTLE – September 27, 2024 – Researchers at Fred Hutch Cancer Center identified a substantial increase over the past decade in the proportion of patients with cancer in the U.S. who participate in ...
The Food & Drug Administration (FDA) issued an updated draft guidance on developing action plans to address clinical trial diversity in support of certain studies of drugs and medical devices.
This study is led by Professor Xin Sun (Institute of Integrated Traditional Chinese and Western Medicine and Chinese Evidence-based Medicine Center, Cochrane China and IDEAL China Center, West China ...
The FDA’s new draft guidance on Bayesian methodology signals a shift toward more flexible, data-driven clinical trial designs, enabling sponsors to use prior data and adaptive approaches to improve ...
Industry sponsors will be required to submit diversity action plans for certain key clinical studies of drugs and devices, according to draft guidance released recently by the US Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback